142 related articles for article (PubMed ID: 20478715)
1. Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases.
Den Hengst WA; Van Putte BP; Hendriks JM; Stockman B; van Boven WJ; Weyler J; Schramel FM; Van Schil PE
Eur J Cardiothorac Surg; 2010 Nov; 38(5):621-7. PubMed ID: 20478715
[TBL] [Abstract][Full Text] [Related]
2. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial.
Hendriks JM; Grootenboers MJ; Schramel FM; van Boven WJ; Stockman B; Seldenrijk CA; ten Broecke P; Knibbe CA; Slee P; De Bruijn E; Vlaeminck R; Heeren J; Vermorken JB; van Putte B; Romijn S; Van Marck E; Van Schil PE
Ann Thorac Surg; 2004 Dec; 78(6):1919-26; discussion 1926-7. PubMed ID: 15561001
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases.
den Hengst WA; Hendriks JM; Balduyck B; Rodrigus I; Vermorken JB; Lardon F; Versteegh MI; Braun J; Gelderblom H; Schramel FM; Van Boven WJ; Van Putte BP; Birim Ö; Maat AP; Van Schil PE
J Thorac Oncol; 2014 Oct; 9(10):1547-53. PubMed ID: 25105436
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
Grootenboers MJ; Hendriks JM; van Boven WJ; Knibbe CA; van Putte B; Stockman B; De Bruijn E; Vermorken JB; Van Schil PE; Schramel FM
J Surg Oncol; 2007 Dec; 96(7):583-9. PubMed ID: 17999399
[TBL] [Abstract][Full Text] [Related]
5. Re-evaluation of toxicity and long-term follow-up of isolated lung perfusion with melphalan in patients with resectable pulmonary metastases: a phase I and extension trial.
Grootenboers MJ; Schramel FM; van Boven WJ; van Putte BP; Hendriks JM; Van Schil PE
Ann Thorac Surg; 2007 Mar; 83(3):1235-6. PubMed ID: 17307516
[No Abstract] [Full Text] [Related]
6. Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model.
Den Hengst WA; Hendriks JM; Van Hoof T; Heytens K; Guetens G; de Boeck G; Lardon F; Van Schil PE
Eur J Cardiothorac Surg; 2012 Aug; 42(2):341-7; discussion 347. PubMed ID: 22345285
[TBL] [Abstract][Full Text] [Related]
7. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial.
van Ijken MG; van Etten B; Guetens G; de Bruijn EA; Ten Hagen TL; Wiggers T; Eggermont AM
Eur J Surg Oncol; 2005 Oct; 31(8):897-904. PubMed ID: 16084053
[TBL] [Abstract][Full Text] [Related]
8. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
9. Isolated lung perfusion for the treatment of pulmonary metastases an experimental study in the rat.
Van Schil P; Hendriks J
Verh K Acad Geneeskd Belg; 1999; 61(4):517-50. PubMed ID: 10500475
[TBL] [Abstract][Full Text] [Related]
10. Anterograde versus retrograde isolated lung perfusion with melphalan in the WAG-Rij rat.
Romijn S; Hendriks JM; Van Putte BP; Weyler J; Guetens G; De Boeck G G; De Bruijn EA; Van Schil PE
Eur J Cardiothorac Surg; 2005 Jun; 27(6):1083-5. PubMed ID: 15896622
[TBL] [Abstract][Full Text] [Related]
11. Effective therapy: repeat limb perfusion for recurrent melanoma.
Krementz ET
J Am Coll Surg; 1996 Jun; 182(6):547-8. PubMed ID: 8646356
[No Abstract] [Full Text] [Related]
12. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Phase II Clinical Trial of Isolated Lung Perfusion in Patients With Lung Metastases.
Beckers PAJ; Versteegh MIM; Van Brakel TJ; Braun J; Van Putte B; Maat APWM; Vergauwen W; Rodrigus I; Den Hengst W; Lardon F; De Bruijn E; Guetens G; De Boeck G; Gielis JF; Lauwers P; Denissen L; Hendriks JMH; Van Schil PE
Ann Thorac Surg; 2019 Jul; 108(1):167-174. PubMed ID: 30951699
[TBL] [Abstract][Full Text] [Related]
14. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver.
Rothbarth J; Pijl ME; Vahrmeijer AL; Hartgrink HH; Tijl FG; Kuppen PJ; Tollenaar RA; van de Velde CJ
Br J Surg; 2003 Nov; 90(11):1391-7. PubMed ID: 14598420
[TBL] [Abstract][Full Text] [Related]
15. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study.
van Etten B; Brunstein F; van IJken MG; Marinelli AW; Verhoef C; van der Sijp JR; Guetens G; de Boeck G; de Bruijn EA; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2004 Jun; 11(6):598-605. PubMed ID: 15172933
[TBL] [Abstract][Full Text] [Related]
16. Isolated lung perfusion with melphalan: pharmacokinetics and toxicity in a pig model.
van der Elst A; Oosterling SJ; Paul MA; Vonk AM; Sparidans RW; van der Sijp JR
J Surg Oncol; 2006 Apr; 93(5):410-6. PubMed ID: 16550578
[TBL] [Abstract][Full Text] [Related]
17. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
18. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
[TBL] [Abstract][Full Text] [Related]
20. Isolated lung perfusion and related techniques for the treatment of pulmonary metastases.
Van Schil PE; Hendriks JM; van Putte BP; Stockman BA; Lauwers PR; Ten Broecke PW; Grootenboers MJ; Schramel FM
Eur J Cardiothorac Surg; 2008 Mar; 33(3):487-96. PubMed ID: 18226538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
